Moderna Reshuffles Board with Ex-Biogen CFO Michael McDonnell Amid $950M Patent Settlement and EU RSV Supply Deal
Key Insights
Moderna appointed former Biogen CFO Michael McDonnell to its Board as a Class II director and Audit Committee member effective July 8, 2026.
David Rubenstein was reassigned from the Audit Committee to the Nominating and Corporate Governance Committee on the same date.
Moderna faces a $950 million payment by July 8 under a global patent settlement with Arbutus (search) over lipid nanoparticle technology, with total potential payout reaching $2.25 billion.
Moderna has announced a series of significant corporate and financial developments, headlined by the appointment of former Biogen CFO Michael McDonnell to its Board of Directors and a looming $950 million patent settlement payment, alongside a new European Union procurement agreement for its RSV (search) vaccine.
Board Reshuffle Brings Financial Heavyweight
Moderna appointed Michael McDonnell to its Board as a Class II director and member of the Audit Committee, effective July 8, 2026. McDonnell brings over 35 years of financial leadership experience, having served as Chief Financial Officer of Biogen from August 2020 through February 2025. His prior CFO roles include tenures at IQVIA, Intelsat, MCG Capital, and EchoStar. He also currently sits on the boards of Merit Medical (search) and Baxter (search).
Concurrent with McDonnell's appointment, David Rubenstein was reassigned from the Audit Committee to the Nominating and Corporate Governance Committee. The board appointment was made upon the recommendation of the Nominating and Corporate Governance Committee, according to the company's SEC filing.
$950 Million Patent Settlement Payment Due
Moderna is obligated to pay $950 million by July 8, 2026, under a global patent settlement with Arbutus (search) concerning lipid nanoparticle technology used in its COVID-19 (search) vaccine. The total payout under the settlement could reach as much as $2.25 billion, with Arbutus expected to receive approximately $179 million of the initial payment.
EU RSV (search) Vaccine Procurement Secured
In a positive commercial development, Moderna won a European Union procurement contract to supply up to 24 million doses of its RSV (search) vaccine, mRESVIA, to six countries over a period of up to four years. The product is authorized for adults in the EU and will be supplied in a single-dose prefilled syringe format.
Analyst Sentiment Remains Mixed
Broker updates on Moderna reflect cautious sentiment. BofA maintained its Underweight rating while raising its price target to $38. RBC lifted its target to $45, and Morgan Stanley raised its target to $39. Analysts cited muted second-quarter expectations, data risk, and ongoing pipeline progress as factors in their assessments.